Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 246-562-2 | CAS number: 25013-15-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From October 1979 to January 1980
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 980
- Report date:
- 1980
Materials and methods
- Principles of method if other than guideline:
- Male and female Fisher rats (15/sex/group) received the substance by oral gavage at dose levels of 0, 50, 100, 300, 700 and 1500 mg/kg bw, in olive oil. One group of 15/sex served as the control and received only the vehicle, in volumes comparable to those received by treated groups. Animals were observed daily, body weight and food consumption was measured weekly. Clinical pathology investigations (haematology, clinical chemistry and urinalysis) were conducted prior to termination in Week 13. All animals were subject to a full necropsy and histopathological examination of a comprehensive range of tissues.
- GLP compliance:
- yes
Test material
- Reference substance name:
- 4-methylstyrene
- EC Number:
- 210-762-8
- EC Name:
- 4-methylstyrene
- Cas Number:
- 622-97-9
- Molecular formula:
- C9H10
- IUPAC Name:
- 1-methyl-4-vinylbenzene
- Test material form:
- liquid
- Details on test material:
- - Batch/lot No.: 10037901
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- F344 Fisher rats were obtained from Charles River Breeding Laboratories, Wilmington, MA. Age at initiation was approx. 6 weeks. Initial body weights were: males 109.0 – 156.8 g and females 81.1 – 124.2 g. Housed singly and commercial rodent ration (Purina Laboratory Chow) and tap water (automated system) freely available.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- olive oil
- Details on oral exposure:
- All animals received 1 mL/kg olive oil. These solutions were made weekly. Dose volumes were then adjusted to take account of test substance. Those dose volumes (mL/kg) were 1.0, 1.06, 1.12, 1.34, 1.79 and 2.69 and were adjusted according to the most recently recorded mean body weight for each group/sex.
- Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- Daily
- Frequency of treatment:
- 13 weeks
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 50 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 700 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 500 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 15 males and 15 females
- Control animals:
- yes, concurrent vehicle
Examinations
- Observations and examinations performed and frequency:
- Mortality: twice daily
Clinical signs: weekly
Body weight: weekly
Food consumption: weekly
Clinical pathology: at termination
Blood samples form the orbital sinus, urine samples overnight in metabolism cages.
Haematology samples were examined for haematocrit, haemoglobin, erythrocyte, platelet count and leukocyte count and differentials.
Clinical chemistry samples were examined for blood urea nitrogen, glucose, Serum glutamic oxaloacetic transaminase (aspartate amino transaminase) creatinine, total protein, albumin, alanine aminotransferase, and alkaline phosphatase.
Urine samples were examined for appearance, pH, specific gravity, ketones, protein, urobilinogen and volume. - Sacrifice and pathology:
- At termination animals were killed by exanguination under sodium pentobarbital. The weight of the brain, heart, kidney, liver, lungs, testis with epididymis and ovaries were recorded.
Tissues were fixed in 10 % neutral buffered formalin. The following tissues were examined: brain, pituitary, spinal cord, eyes, mandibular salivary gland, thyroid, thymus, trachea, oesophagus, lungs, heart, liver, spleen, kidneys, adrenals, stomach, pancreas, duodenum, jejunum, ileum, colon, cecum, mesenteric lymph nodes, urinary bladder, testes with epididymides, prostate, ovaries, uterus, femur, bone marrow and any unusual lesions. The following tissues were examined microscopically: lungs, liver, kidneys, testes, ovaries, prostate and uterus. - Statistics:
- For body weight, food consumption clinical pathology and organ weight data the test groups were compared to the control group using Bartlett’s test for homogeneity of variance followed by one-way ANOVA if the variance was homogenous. Non-homogenous data was log transformed. If ANOVA was significant Scheffe’s multiple pair-wise comparisons of Games and Howell’s multiple pair-wise comparisons were used. All analysis conducted at the 5% probability level.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, non-treatment-related
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- 1500 mg/kg/day exceeded the MTD and were associated with notable mortality. Deaths were also observed at 300 (1/30) and 700 (3/30) mg/kg/day.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Male body weight was lower than control in all treated groups; there was no similar effect in females.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- In males, some statistically significant differences in organ weights were considered to reflect the reduced body weight, and not a direct effect of treatment. However, liver weight was increased at 300 mg/kg/day and greater and kidney weight at 700 mg/kg/day and greater.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- In animals given 700 or 1500 mg/kg/bw per day there were some changes that were considered to reflect dehydration rather than a direct toxicological change. These included increased packed cell volume and erythrocyte count and increases in total protein and albumin values. There were no urinalysis findings of note. The only change considered to be related to treatment was an increase in blood urea nitrogen values but this was not dose related and the increase above control level was small.
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Lungs: Severe irritation of the bronchial and bronchiolar epithelium with focal sloughing of the respiratory epithelium with histiocytic filling of the eroded foci; peribronchial and peri bronchiolar fibrosis; focal bronchietasis; hyper-secretion of mucous with-in airways often accompanied by mucous lake formation within alveoli; and occasional perivascular and peribronchial aggregates of eosinophils at 700 and 1500 mg/kg. There was no NOEL for the exacerbation of multifocal chronic pneumonitis and focal hyperplasia of bronchial and bronchiolar epithelium. Control animals usually had focal areas of minimal to slight pneumonitis, whereas treated animals more frequently had lesions of moderate severity.
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not specified
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Remarks on result:
- not determinable due to adverse toxic effects at highest dose / concentration tested
- Key result
- Dose descriptor:
- LOAEL
- Effect level:
- 50 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Lung pathology: exacerbation of multifocal chronic pneumonitis and focal hyperplasia of bronchial and bronchiolar epithelium apparent in all treated groups
Target system / organ toxicity
- Key result
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Under the study conditions, the LOAEL was considered to be 50 mg/kg bw/day, the lowest dose tested.
- Executive summary:
A study was conducted to determine the repeated dose oral toxicity of the test substance when administered to rats daily for 13 weeks. Male and female Fisher rats (15/sex/group) received the substance by oral gavage at dose levels of 0, 50, 100, 300, 700 and 1500 mg/kg bw/day, in olive oil. One group of 15/sex served as the control and received only the vehicle, in volumes comparable to those received by treated groups. Animals were observed daily, body weight and food consumption were measured weekly. Clinical pathology investigations (haematology, clinical chemistry and urinalysis) were conducted prior to termination in Week 13. All animals were subject to a full necropsy and histopathological examination of a comprehensive range of tissues. Following mortalities were recorded during the course of the study: one male in dose group 300 mg/kg bw/day, one male in dose group 700 mg/kg bw/day, two females in dose group 700 mg/kg bw/day, nine females in dose group 1500 mg/kg bw/day. The survival rate of the 1500 mg/kg bw/day dose group males and females was significantly lower than that of the respective control group. Gross pathology findings of lung (hypersecretion of mucous) and stomach alterations were the most notable observations in this dose group. The lung was identified as a target organ and there was no NOEL for the exacerbation of multifocal chronic pneumonitis and focal hyperplasia of bronchial and bronchiolar epithelium, which as observed in all treated groups at a greater severity than in the controls. Comparison of the hematology data between the control and treated groups revealed significantly higher than control value in the mean hematocrit value in the highest dose group males and females and in the mean erythrocyte count in the highest dose group in females. Male body weight was lower than control in all treated groups, there was no similar effect in females. Liver weight was increased at 300 mg/kg bw/day and greater and kidney weight at 700 mg/kg bw/day and greater. No treatment–related effects were noted in comparison of the urinalysis. Under the study conditions, no NOAEL was identified. The LOAEL was considered to be 50 mg/kg bw/day, the lowest dose tested (Wolfe, 1980).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
